4.88
4.88 (0%)
As of Feb 14, 2025
4d Molecular Therapeutics, Inc. [FDMT]
Source:
Company Overview
4d Molecular Therapeutics, Inc is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients.
| Country | United States |
| Headquarters | emeryville, california |
| Phone Number | (510) 505-2680 |
| Industry | manufacturing |
| CEO | David Kirn, M.D. |
| Website | www.4dmoleculartherapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-187.8 |
| Net Income | $-160.9 |
| Net Cash | $-99.8 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | -507,678.4 |
| Profit as % of Revenues | -0% |
| Profit as % of Assets | -35.7% |
| Profit as % of Stockholder Equity | -31.5% |
Management Effectiveness
| Return on Equity | -31.5% |
| Return on Assets | -28.7% |
| Turnover Ratio | 0% |
| EBITA | $-187.8 |
Balance Sheet and Cash Flow Measures
| Total Assets | $560.4 |
| Total Liabilities | $49.8 |
| Operating Cash Flow | $-134.6 |
| Investing Cash Flow | $-302.4 |
| Financing Cash Flow | $337.3 |
